To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Novocell Announces Non-Exclusive Drug Discovery Collaboration with Pfizer
Read time: Less than a minute
Novocell, Inc.
has announced that it has entered into a non-exclusive drug discovery collaboration with
Pfizer
giving Pfizer access to Novocell’s proprietary pancreatic progenitor cells derived from human embryonic stem (hES) cells.
Under terms of the agreement, Novocell will receive an upfront payment with additional amounts payable upon the achievement of certain technical milestones, as well as research funding.
In addition, Novocell will receive payments relating to the sale by Pfizer of any exclusive therapeutic discovered as a result of the collaboration. The duration of the research collaboration will be 2 years with the option by Pfizer to extend.
“We are very pleased to collaborate with Pfizer, an industry leading pharmaceutical company with a strategic vision about regenerative medicine. This joint opportunity takes advantage of our leading stem cell engineering technologies and Pfizer’s expertise in drug discovery, providing for innovative, regenerative therapeutics,” said Alan J. Lewis, Ph.D., President and Chief Executive Officer of Novocell.
Under terms of the agreement, Novocell will receive an upfront payment with additional amounts payable upon the achievement of certain technical milestones, as well as research funding.
In addition, Novocell will receive payments relating to the sale by Pfizer of any exclusive therapeutic discovered as a result of the collaboration. The duration of the research collaboration will be 2 years with the option by Pfizer to extend.
“We are very pleased to collaborate with Pfizer, an industry leading pharmaceutical company with a strategic vision about regenerative medicine. This joint opportunity takes advantage of our leading stem cell engineering technologies and Pfizer’s expertise in drug discovery, providing for innovative, regenerative therapeutics,” said Alan J. Lewis, Ph.D., President and Chief Executive Officer of Novocell.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
